AstraZeneca India has launched a clinical data and insights division in India to further strengthen its global presence and for the management of data-related aspects of its clinical trials. The clinical data and insights team in Bengaluru is a critical advancement to support a growing global portfolio and build on internal data expertise. With the centre starting its operations recently, the team will continue to expand by sourcing the right talent and resources for future needs.

Reporting into Development Operations in Biopharmaceuticals R&D, the Clinical Data & Insights (CDI) team is responsible for the management of data-related aspects of AstraZeneca's clinical trials, excluding analysis and reporting.

CDI division works across therapy areas and portfolios, supporting early and late-stage clinical programmes from Phase 1 to Phase 3 with an integrated end-to-end approach for clinical data, analytics, insights and risk management. Currently a 30-member team, the division is expected to grow to a 100+ member strong team by 2022.
 
AstraZeneca CDI's current footprint includes over 400 employees and approximately 700 data management professionals in vendor partnerships across six countries. They are now embedding data science and Artificial Intelligence (AI) across R&D centres to enable their data teams to push the boundaries of science to deliver life-changing medicines.